CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0603 (clinicaltrials.gov NCT No: NCT00833807)
Title:PHASE I STUDY OF HEPATIC ARTERIAL INFUSION OF NAB-PACLITAXEL (ABRAXANEŽ) IN PATIENTS WITH METASTATIC MELANOMA IN THE LIVER
Principal Investigator:Agop Y. Bedikian
Treatment Agent:Abraxane
Study Status:Closed
Study Description:The goal of this clinical research is to find the highest tolerable dose of
Abraxane (nab-paclitaxel) when given directly to the area where the cancer is
located. The safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:Abraxane
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:2 days every 3 weeks.
Supported By:Abraxis Bioscience
Abraxis Bioscience
Return Visit:Every 3 weeks
Home Care:No


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Agop Y. Bedikian
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults